Cleared Traditional

K220105 - Saige-Dx
(FDA 510(k) Clearance)

May 2022
Decision
120d
Days
Class 2
Risk

K220105 is an FDA 510(k) clearance for the Saige-Dx. This device is classified as a Radiological Computer Assisted Detection/diagnosis Software For Lesions Suspicious For Cancer (Class II - Special Controls, product code QDQ).

Submitted by DeepHealth, Inc. (Cambridge, US). The FDA issued a Cleared decision on May 12, 2022, 120 days after receiving the submission on January 12, 2022.

This device falls under the Radiology FDA review panel. Regulated under 21 CFR 892.2090. A Radiological Computer Assisted Detection And Diagnostic Software For Suspected Lesions Is An Image Processing Device Intended To Aid In The Detection, Localization, And Characterization Of Lesions Suspicious For Cancer On Acquired Medical Images (e.g., Mammography , Mr, Ct, Ultrasound, Radiography). The Device Detects, Identifies And Characterizes Lesions Suspicious For Cancer Based On Features Or Information Extracted From The Images, And May Provide Information About The Presence, Location, And Characteristics Of The Lesion To The User. Primary Diagnostic And Patient Management Decisions Are Made By The Clinical User..

Submission Details

510(k) Number K220105 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received January 12, 2022
Decision Date May 12, 2022
Days to Decision 120 days
Submission Type Traditional
Review Panel Radiology (RA)
Summary Summary PDF

Device Classification

Product Code QDQ — Radiological Computer Assisted Detection/diagnosis Software For Lesions Suspicious For Cancer
Device Class Class II - Special Controls
CFR Regulation 21 CFR 892.2090
Definition A Radiological Computer Assisted Detection And Diagnostic Software For Suspected Lesions Is An Image Processing Device Intended To Aid In The Detection, Localization, And Characterization Of Lesions Suspicious For Cancer On Acquired Medical Images (e.g., Mammography , Mr, Ct, Ultrasound, Radiography). The Device Detects, Identifies And Characterizes Lesions Suspicious For Cancer Based On Features Or Information Extracted From The Images, And May Provide Information About The Presence, Location, And Characteristics Of The Lesion To The User. Primary Diagnostic And Patient Management Decisions Are Made By The Clinical User.

Similar Devices — QDQ Radiological Computer Assisted Detection/diagnosis Software For Lesions Suspicious For Cancer

All 30
Median LCS (internal name) / eyonis LCS (trade name) (1.0)
K251474 · Median Technologies · Feb 2026
Saige-Dx
K251873 · DeepHealth, Inc. · Aug 2025
Genius AI Detection 2.0
K243341 · Hologic, Inc. · Jul 2025
MammoScreen? (4)
K243679 · Therapixel · Jul 2025
QP-Prostate? CAD
K242683 · Quibim S.L. · Mar 2025
Prostate MR AI (VA10A)
K241770 · Siemens Healthcare GmbH · Mar 2025